Bronchopulmonary cancer is the 2nd most frequent cancer affecting men and the 3rd most frequent cancer affecting women. It is the leading cause of death (all causes considered) in men between 45 and 64 years of age. It is the second most common cause of cancer death for women after breast cancer.

The prognosis of the disease is correlated with the resectability of the tumor, the stage of the disease, the histological type, the speed of diagnostic and therapeutic management and the general condition of the patient.

The main risk factor for bronchopulmonary cancer is active or passive smoking. Other environmental or occupational factors are recognized as carcinogens, in particular asbestos and diesel exhaust.

Estimated number of new cases in 2020
worldwide, men/women, all ages combined


1. Treatment of non-small cell lung cancer


the only curative treatment for non- small cell bronchial cancer.
Surgery is the treatment in stage I and II cancers, and for some stage III cancers, in association or not with chemotherapy and radiotherapy.

POST-OPERATIVE CHEMOTHERAPY AND/OR POST-OPERATIVE RADIATION are discussed depending on the analysis of the removed tissue.

  • STAGE III NON-OPERATIONAL tumors: in this case combined use of chemotherapy with radiotherapy.
  •  STAGE IV tumors associated with metastases: in this case the treatment is general, using chemotherapy, immunotherapy, and targeted biotherapies.

When the risk of surgery is too high, it is possible to use stereotactic radiotherapy, i.e. irradiation highly focused on the lung tumor; its effectiveness is equivalent to that of surgery in this context.

1.2. New strategies : IMMUNOTHERAPY

Administered before or after surgery and after radiotherapy, to prevent the risk of recurrence.

2. Treatment of small cell bronchial cancer

Two-thirds of small-cell bronchial carcinomas are diagnosed at the metastatic stage.

Chemotherapy combined with immunotherapy is the standard treatment for metastatic small cell cancer.

The treatment of small cell cancer in the chest is based on the delivery of chemotherapy and radiation therapy.


Surgyone offers you a medical supervision by state-of-the-art teams (combining organ specialists, specialized surgeons, anesthesiologists, anatomical pathologists and specialized oncologists).

The surgical or endoscopic techniques required to manage your pathology are part of the current surgical excellence (conventional surgery, minimally invasive surgery, robotic surgery, interventional endoscopy).

In the context of the management of cancer-related pathologies, all decisions will be taken during multidisciplinary consultation meetings related to this pathology.

SurgyOne helps you with the following pathologies :

Bronchopulmonary cancers

Benign bronchopulmonary tumors

> Diseases of the pleura

  • Pleural tumor
  • Pleurisy (pleural effusion)
  • Pneumothorax

> Pathologies and tumors of the mediastinum

  • Benign tumor of the mediastinum
  • Cancerous tumor of the mediastinum
Get in touch with SurgyOne

Surgical pathology information request

Feel free to contact our team by email or by phone

By email

By phone

+33 (0)4 22 72 02 22
( 24h/24 - 7d/7 )

Tell us about you

To contact you

Your request